After completing a successful phase I partnership with TFS International (TFS), Araclon Biotech decided to continue the partnership advancing their Alzheimer’s disease (AD) vaccine ABvac40 into phase II.  The placebo-controlled phase II trial will be carried out at 21 clinical investigational sites across Europe over the next two years.   ABvac40 is an active immunotherapy that uses the C-terminal fragment of the amyloid-beta 40 peptide as an immunogen.  This is a different approach to o...